The purpose of this research was to explore the utility of β cyclodextrin (βCD) and β cyclodextrin derivatives (hydroxypropyl-β-cyclodextrin [HPβCD], sulfobutylether-β-CD [SBβCD], and a randomly methylated-β-CD [RMβCD]) to form inclusion complexes with the antitumoral drug, β-lapachone (βLAP), in order to overcome the problem of its poor water solubility. RMβCD presented the highest efficiency for βLAP solubilization and was selected to develop solid-state binary systems. Differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), Fourier transform infrared (FTIR) and optical and scanning electron microscopy results suggest the formation of inclusion complexes by both freeze-drying and kneading techniques with a dramatic improvement in drug dissolution efficiency at 20-minute dissolution efficiency (DE 20-minute 67.15% and 88.22%, respectively) against the drug (DE 20-minute 27.11%) or the βCD/drug physical mixture (DE 20-minute 27.22%). However, the kneading method gives a highly crystalline material that together with the adequate drug dissolution profile make it the best procedure in obtaining inclusion complexes of RMβCD/βLAP convenient for different applications of βLAP.
INTRODUCTION
β-lapachone (βLAP) is a naphtoquinone obtained on a small scale from South American trees of the families Bigoniaceae and Verbenaceae ( Figure 1 ). 1 On a larger scale it can be produced following the method developed by Hooker and coworkers through cyclization of lapachol in sulphuric acid by nucleophilic attack of oxygen of the isoprenyl side chain and purification by further recrystallizations. 2 Over the last few years β-lapachone has been reported to possess a wide range of pharmacological properties. It has antifungal, antiviral, antibacterial, anti-psoriatic, antiinflammatory activities and also is an active agent against parasites such as Trypanosoma cruzi, the etiologic agent of Chagas disease. [3] [4] [5] [6] [7] [8] However, its antineoplasic activity has certainly generated the greatest expectations on the molecule. In vitro and in vivo studies have shown that β-lapachone inhibits conventional therapy-resistant tumors, particularly the proliferation of neoplasms of slow cell cycle such as prostate, pancreatic, colon, and some ovarian and breast cancers. [9] [10] [11] [12] Despite its interesting potential applications, tests on humans and clinical trials have not yet been performed. The low water solubility of β-lapachone, 0.038 mg·mL −1 , probably the cause of a low and erratic bioavailability, is the first problem to overcome in the development of dosage forms including the drug. 13 Cyclodextrins (CDs) are cyclic oligosaccharides with lipophilic inner cavities and hydrophilic outer surfaces capable of interacting with a large variety of drugs giving noncovalent inclusion complexes that have been used extensively to improve solubility, dissolution rate, bioavailability, and stability.
14 Drugs such as β-lapachone, having aqueous solubility in micromole/liter range are good candidates for solubility enhancement through CD complexation. 15 Cyclodextrins have been shown to increase the solubility of β-lapachone as studied by Nasongkla and coworkers but the available information on this subject is extremely limited, particularly on solid systems. 16 The use of α, β, hydroxypropyl-β (HPβ), and γ CDs has been explored, concluding that βCD and especially HPβCD are useful in achieving an increase of water solubility up to 400-fold and overcoming the problem of parenteral administration. 16, 17 However, with a view to use the oral route, the difficulty is maintained.
A limiting factor in selecting the appropriate CD for a formulation is the amount of complex to be administered. A dosage form for the oral route, a tablet for example, should not exceed 500 mg to 1 g. Since βLAP has a molecular weight of 242.3 and HPβCD of 1390, 100 mg of a complex βLAP/HPβCD 1:1 contains~14.8 mg of βLAP. It would be useful to find a CD derivative with a higher capacity of increasing βLAP solubility. 18 On this basis, the main purpose of this research was to explore and compare, using a solubility diagram method, the utility of βCD derivatives to form inclusion complexes with βLAP in order to improve the capacity of increasing βLAP solubility. Four CDs have been selected: βCD and HPβCD, previously reported by Nasongkla and coworkers, and 2 additional βCD derivatives, sulfobutylether-β-cyclodextrin (SBβCD) and a randomly methylated-β cyclodextrin (RMβCD). 19 Solid drug-RMβCD binary systems were prepared according to different techniques (physical mixing, kneading, and freeze-drying) and characterized by differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), Fourier transform infrared (FTIR) spectroscopy, and optical and scanning electron microscopy (SEM) in order to achieve an improvement on βLAP dissolution properties useful for different applications. is 99.9%. βCD and RMβCD (degree of molar substitution 0.57) were kindly donated by Roquette (Barcelona, Spain); HPβCD (degree of molar substitution 2.7) was a Janssen Pharmaceutica (Beerse, Belgium) gift and SBβCD (degree of molar substitution 1.0) was a CyDex (Lenexa, KS) gift. All the βCD derivatives have an aqueous solubility higher than 20% (wt/vol). All other materials were of analytical grade. The solutions were prepared using distilled water and filtered through 0.22-μm Millipore filters (Millipore Corp, Billerica, MA).
MATERIALS AND METHODS

Materials
β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b] pyran-5,
Analytical Methods
Α UV spectrophotometric method was developed for quantitative βLAP determination using a UV-visible spectrophotometer Agilent 8453 (Agilent Corp, Santa Clara, CA) with photodiode array detector at 257 nm. Calibration curve in water/ethanol (1:1 vol/vol) was made using standard solutions in the range of 2 to 10 µg mL
. The molar extinction coefficient found was 2.452×10 4 absorbance units.
No effect of the addition of cyclodextrins on the UV spectrum of βLAP solution was verified by comparison of βLAP and CDs/βLAP spectra for any of the CDs studied.
Drug chemical integrity on the liquid and solid systems was evaluated by HPLC analysis using a Waters M600 apparatus with photodiode array detector (Waters Corp, Milford, MA) equipped with a 5-µm C18 cartridge (125 × 4 mm) according to a previously reported method. 20 
Phase Solubility Studies
Phase solubility studies were performed according to the method reported by Higuchi and Connors. 21 Excess amounts of βLAP (~15 mg) were added to 3 mL of aqueous solutions containing increasing concentrations of CDs, in the range of 0% to 1% (wt/vol) for βCD; 0% to 2% (wt/vol) for HPβCD; 0% to 3% (wt/vol) for RMβCD; and 0% to 4% (wt/vol) for SBβCD. Suspensions were introduced into an ultrasound bath for 15 minutes and shaken in an oscillating water bath thermostatically controlled at 25-C for 7 days, enough time to guarantee the equilibrium, according to previous studies. Samples were filtered and appropriately diluted. βLAP concentration was determined spectrophotometrically. Experiments were performed in triplicate. The drug-CD association constants (K 1:1 ) were calculated, from the linear portion of the phase solubility diagrams assuming a 1:1 stoichiometry, using the following equation:
where S 0 is βLAP water solubility in the absence of CD. 
Preparation of Solid βLAP-RMβCD Systems
Preparation of Kneaded Systems
The kneaded system (KN) was prepared from physical mixture in a mortar by slowly adding ethanol/water (1:1 vol/vol), in an amount of 20% wt/wt, and mixing until the homogeneous system was obtained. 22 Samples were dried in an oven at 40-C for 24 hours and powdered. A granulometric fraction (100-250 µm) was selected and characterized.
Preparation of Freeze-dried Systems
The physical mixture was dissolved in ethanol:water (1:1 vol/vol). The solution was frozen by immersion in liquid nitrogen and freeze-dried (FD) in a Labconco apparatus (Labconco Corp, Kansas City, MO). A 100-250 µm sieve granulometric fraction was collected for further characterization.
Solid βLAP-RMβCD System Characterization
X-ray Powder Diffraction
The X-ray powder diffraction patterns were collected using copper radiation (40 Kv, 30 mA), on a Philips PW 1729 diffractometer (Philips Corp, Netherlands) with Bragg-Brentano geometry, in the 2G2θG60 range with a step size of 0.02º and counting time of 2 seconds per step. The microstructure study of the measured samples was determined through line profile analysis (LPA), which included a profile fitting stage to extract profile information from the powder diffraction peaks.
In order to compare the relative crystallinity of β-lapachone in the analyzed samples, the microstructural factor crystallite size was obtained using the analysis of the profile information by inverting the Warren-Averbach procedure. 23, 24 A WinPLOTR software that implements the LPA method was used. 25 On this basis it is possible to obtain
where D v is the volume-weighted domain size, Beta_G(corrected) is the Gaussian contribution to the integral breath after the instrumental broadening correction, λ represents the wavelength, and θ the peak Bragg angle. The instrumental profile component was determined experimentally
by means of suitable profile standards. 26 As a further general assumption, we consider that the best polycrystalline analyzed sample with coherent diffraction crystallites is sufficiently small to provide an appropriate standard for the correction of the instrumental broadening.
Differential Scanning Calorimetry
Samples weighing 2 to 3 mg were placed in open aluminum pans and heated from 30-C to 250-C at a rate of 10-C·min −1 using a temperature modulated DSC Q100 calorimeter (TA Instruments, New Castle, DE). Nitrogen was used as purge gas at a flux rate of 50 mL·min
. Calibration of temperature and heat flow was performed with standard indium samples. All measurements were performed in triplicate. The percentage of βLAP in the original crystalline form (OCF) in the binary systems was calculated by the following equation 27 :
where ΔH BS is the fusion enthalpy of β-lapachone in the binary system and ΔH PD is the fusion enthalpy of pure βLAP.
Fourier Transform Infrared Spectroscopy
Infrared spectra were obtained using a Bruker IFS-66V spectrometer (Bruker Daltonics Inc, Bremen, Germany). Samples were ground, mixed thoroughly with potassium bromide, and compressed in a hydraulic press. Thirty-two scans were obtained at a resolution 4 cm −1
.
Optical and Scanning Electron Microscopy
Optical morphological characteristics of the βLAP-CD systems were analyzed using an Olympus SZ60 (Opelco, Tokyo, Japan) optical microscope (OM) connected to a video camera Olympus DP12 (Opelco). The images were processed using Analysis version 3.2 (Analysis Software, Müster, Germany). Samples surface morphologies were examined using a LEO-435VP scanning electron microscopy (Leica Microsystems, Cambridge, UK). Particles were fixed on a brass stub using double-sided tape and gold coated in vacuum.
Dissolution Studies
In vitro dissolution studies were performed following Food and Drug Administration (FDA) specifications for poor soluble drugs using a United States Pharmacopeia (USP) dissolution apparatus 2 (paddle) (Turu Grau DT-6, Barcelona, Spain) at 75 rpm and 37-C (±0.5-C). In order to ensure sink conditions and increase the ability of the dissolution test to distinguish between formulations, the solubility of βLAP in water-containing surfactants were tested. A volume of 900 mL of aqueous solution of sodium lauryl sulfate at a concentration of 0.5% was selected as dissolution medium (solubility of βLAP in the dissolution medium selected was 0.163 mg mL
). 18 Powdered samples of 50 mg of βLAP or equivalent amounts of each βLAP/CD system (particle size 100-250 µm) were tested. Powdered samples were submerged rapidly in the medium. At certain time intervals samples were collected, filtered through cellulose filters, and the concentration of drug dissolved determined by spectroscopy at 257 nm. For each binary system 3 replicates were tested. The dissolution profiles were evaluated and compared using the dissolution efficiency at 20-minute dissolution efficiency (DE 20 ) parameter. 29 The statistical analysis of the DE 20 was performed by the 1-way analysis of variance (ANOVA) followed by least significant difference test using Statgraphics Plus version. 30 
RESULTS AND DISCUSSION
Phase Solubility Diagrams
The effect of selected CDs on the aqueous solubility of βLAP (0.1264 mM) was evaluated using the phase solubility diagrams ( Figure 2 ). The enhancement of βLAP solubility was highly dependent on the type of βCD. In all cases, the solubility of βLAP increased linearly as a function of cyclodextrin concentration over the studied concentration range with slopes lower than one (Table 1) . Diagrams can be classified as A L type and suggest a 1:1 mol:mol βLAP-CD stoichiometry, according to Higuchi and Connors. 21 Association constants estimated for βLAP-βCD and βLAP-HPβCD were in agreement with previous data reported by Nasongkla and coworkers (1.23 10 3 M −1 for βCD and 0.94 10 3 M −1 for HPβCD). 16 The SBβCD and RMβCD, not yet evaluated in previous studies, had higher solubilizing effect on the drug than βCD and HPβCD. The association constant (K 1:1 ) obtained with RMβCD was almost 2 times higher than with the other βCD derivatives. The solubilization performance of RMβCD could be derived from the presence of the methyl groups, which can extend the hydrophobic region of the cyclodextrin cavity favoring and stabilizing the inclusion complexation of the βLAP molecule. 31 A similar effect occurs also with the hydroxypropyl or the sulfobutil ether groups but results suggest more favorable molecular interaction within the methyl groups.
As it was indicated earlier, for a solid oral formulation it would be useful to select the CD derivative with the highest capacity of increasing βLAP solubility. Therefore, the general characteristics of methylated βCD, especially its high aqueous solubility and low toxicity together with its higher efficiency for βLAP solubilization made RMβCD the candidate for inclusion in an oral solid dosage form. 32 
Preparation and Characterization of βLAP-RMβCD Systems
When a cyclodextrin and a potential guest are subjected to a treatment, there is no guarantee that a real inclusion complex will be produced. It has been reported that the product can be a mixture of complex, uncomplexed guest, empty cyclodextrin, and also different kinds of drug-CD interactions. As a consequence, a cautious physical-chemical analysis has to be performed to clarify the interactions between the components and its effects on the properties of interest. 22 The chemical stability of the drug in the solid systems was evaluated by HPLC, finding neither chemical incompatibilities between components nor changes resulting from the stress of the process. 
X-ray Powder Diffraction
The possible XRPD patterns of βLAP are shown in Figure 3 . βLAP presents a typical polycrystalline diffraction pattern, exhibiting a main sharp peak at 9.5 º2θ and secondary peaks at 13.05, 19.05, 19.59, 24.67, and 39.31 º2θ. The profile slightly changes in the βLAP powdered sample (100-250 µm). The preferred orientation variation on the analyzed crystallites could explain these differences because the relative intensity of the peaks showed changes. An ideal distribution of the crystallites can be seen at βLAP simulated pattern obtained from the single crystal data, where there is not preferred orientation at all. 33 The XRPD pattern of RMβCD as supplied shows a diffuse pattern typical of an amorphous product. As can be seen in Figure 4 , the pattern of the PM of βLAP-RMβCD can be obtained by the superimposition of pure component patterns. However, the kneading βLAP-RMβCD system XRPD profile presents a great change, involving new peaks, compared with the PM, which could be explained by crystallographic modifications performed during the formulation process. In order to understand such changes, RMβCD without drug was subjected to a kneading process under the same conditions. The product obtained (RMβCD kneading ; Figure 4 ) and RMβCD, as supplied, show completely different X-ray diffraction patterns, peak relative intensities, and shape, suggesting that the kneading process promotes the cyclodextrin crystallization. RMβCD has a random distribution of a few sterically small methyl groups that do not completely block the ability to form crystals on the contrary to other βCD derivatives.
Finally, the FD system seems to have the greatest pattern difference. The differences cannot be explained by the simple addition of the components, suggesting a clear interaction between the compounds.
In order to obtain the βLAP relative crystallinity from the analyzed samples, LPA was focused on the βLAP main peak. Figure 5 shows the normalized main peaks for the βLAP pure component and for the binary samples. Changes on the peak profile depending on the treatment can be seen. This finding confirms different microstructure properties. Assuming that the βLAP main peak was small enough to provide an appropriate standard for the correction of the instrumental broadening, it is possible to state that the FD system presents the lowest crystallinity with a Dv of 538. . This could be explained by the appearance of another kind of crystalline form for the KN system, which is different from the original and that makes this system more crystalline than the PM. 
Differential Scanning Calorimetry Analysis
DSC analyses of raw materials and binary systems studied are shown in Figure 6 and Table 2 . It can be seen that the βLAP DSC curve displays a sharp endotherm at 157.3-C, which is due to drug melting, characteristic of an anhydrous crystalline substance. RMβCD exhibits a broad endothermic effect ranging between 30-C and 149-C associated with water loss from inside the cavity.
Disappearance of the fusion peak of the drug is often interpreted as evidence of an inclusion complex formation. In the present study, the thermal profiles of all the binary systems showed the drug melting peak of βLAP, indicating the presence of unchanged drug in all the preparations, which is in agreement with XRPD data. The βLAP pattern in the PM was substantially unaffected in its shape and peak temperature, but a new small exothermic event was detected at 178.6-C (Table 2 ). This finding could be associated with a strong interaction between the CD and the melted drug and subsequent βLAP entrance into the empty CD cavity in an energetic favored process that decreased the energy of the system. 34 The phenomenon is still detectable and reproducible for the KN sample but not for the FD sample.
The DSC curves for KN and FD systems presented a slight shift in the melting peak of βLAP and an important reduction in the values of the associated enthalpy (Table 2 ). In addition, the KN system thermogram shows an extraendothermic event possibly associated with a new crystalline form of the drug-CD complex as suggested by XRPD results.
An enthalpy reduction of the dehydration peak of RMβCD kneading with respect to the RMβCD as supplied can be seen (Figure 6 ), which could be attributed to the crystallization of the CD in a less hydrated form during the process of kneading (confirmed by XRPD and microscopy analysis). 27 A large reduction in the dehydration enthalpy takes place in the FD system and could be explained by the replacement of water molecules inside the CD for drug molecules during the freeze-drying process.
The OCF parameter (Table 2) shows important reductions for FD (25%) and KN (49%) systems, indicating that residual original drug crystallinity is higher in the FD formulation than in the KN system. The combination of XRPD data and DSC suggests that the FD system presents a higher percentage of uncomplexed βLAP with a lower crystallinity degree. On the contrary, the KN system presents a lower percentage of uncomplexed drug but probably the procedure promotes the generation of new crystal phases with an additional associated endotherm at 160.3-C (Table 2) . 35 
Fourier Transform Infrared Spectroscopy
The FTIR analysis is a useful technique to assess the interaction and the complex formation between drug molecules and CDs in the solid state. Shifts or intensity changes in the characteristic bands of pure substance are considered as evidence of the complex existence. 36 However, some changes are very subtle, requiring careful interpretation of the spectra. 
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Infrared spectra of βLAP, RMβCD, and the binary systems PM, KN, and FD are presented in Figure 7 and in Table 3 .
The KN system shows a reduction in the band at 2978 cm −1 corresponding to C-H links of βLAP aromatic region compared with PM ( Figure 7, Line 1) , while the FD system shows the almost complete disappearance of this band.
In the region of 1700-1000 cm −1 , where RMβCD shows a broad band and βLAP did not overlap in the PM, the band corresponding to C=O group ( Figure 7 , Line 2) at 1695 cm −1 was clearly reduced in the FD system. Even for this preparation, bands corresponding to C-C links of aromatic region (Table 3 , Line 4) presented a marked reduction in intensity and a shift to higher frequencies. In the region of C-O-C link (Table 3 and Figure 7 , Lines 5 and 6), both KN and FD systems were affected by variations of the corresponding peak.
The results suggest that the inclusion of the drug inside the RMβCD cavity should take place by the aromatic group side (Figure 1) . Although, the overlapping of drug-CD peaks in the methyl region of the molecule does not permit the rejection of the hypothesis of complexation on this side of the molecule.
Line 3 (Figure 7 ) represents the RMβCD characteristically O-H band linked with water. 18 A broadening of this band in the KN and FD systems could be explained by changes in the CD capacity of hydration, and it is additional evidence of a possible inclusion complex formation. 
Optical and Scanning Electron Microscopy
Morphological changes can be employed as a tool for evidence of interaction between molecules and complex formation. 36, 37 Selected photomicrographs by OM and SEM of the binary systems are presented in Figure 8 . Orange crystals of βLAP surrounded by amorphous RMβCD particles are detectable in the PM system (PM1). There was not apparent interaction between both components in PM. On the contrary, significant modifications in color and shape were observed after kneading or freeze-drying. The KN system presented granular agglomerates of a strong orange color. It was not possible to distinguish between the 2 components (Figure 8, KN1 ). SEM ( Figure 8, KN2 ) shows compact bulky particles as correspond to a crystalline material (eg, XRPD pattern, Figure 4 ).
The FD system (Figure 8, FD1) showed a heterogeneous system with yellow particles dotted with orange crystals. SEM ( Figure 8, FD2 ) presents a mixture of small amorphous particles and acicular crystals. Results confirm the XRPD and DSC data.
Dissolution Studies
Dissolution profiles of β-lapachone and equimolar binary systems βLAP-RMβCD as well as its dissolution efficiencies at 20 minutes are presented in Figure 9 .
The increments in dissolution from inclusion complexes for different drugs have been explained on the basis of a higher energetic amorphous state/reduction of crystallinity, a lower interfacial tension between water-insoluble drug, and the dissolution medium induced by the CD and a greater water solubility of the complex. 37 It is interesting to note that the PM of RMβCD with βLAP does not contribute significantly to an improvement of drug dissolution rate, indicating that the increment in local solubilization action of the CD does not explain the dissolution profile of the system. FD and, especially KN, systems showed profiles with nearly 100% drug dissolved at 5 minutes. The comparison of drug release profiles was made by the calculation of dissolution efficiency parameter at 20 minutes. The ANOVA of the DE 20 for the different systems showed significant differences among formulations (α G 0.05), and the least significant differences test presented 3 subsets. The dissolution rate was higher in the following order: βLAP PM G FD G KN.
The formation of readily soluble complexes by freeze-drying or kneading could be deduced in accordance with previous physicochemical characterization. A reduction in the degree of crystallinity is often associated with an increase in solubility. 27 However, in this case, the degree of crystallinity does not seem to be the only reason involved in the solubility change and probably the generation of new crystal phases (confirmed by XRPD) by the formulation process leading to distinctive microstructural properties is responsible for the different dissolution properties of the KN system. Small differences in the drug solubility rate between KN and FD systems should be related to the variability in the particle structure (Figure 8 ), which determines its wettability and deaggregation properties. Moreover, the crystallinity of KN system should improve manufacturability of the product.
CONCLUSION
In conclusion, the βCD derivatives studied, SBβCD and especially RMβCD, present high efficiency for βLAP solubilization. The results suggest that RMβCD possibly forms inclusion complexes by both freeze-drying and kneading techniques with a dramatic improvement in drug dissolution rate against the drug or the βCD/drug physical mixture. However, the kneading method gives a highly crystalline material that together with the adequate drug dissolution profile make it the best procedure in obtaining inclusion complexes of RMβCD/βLAP convenient for different applications of βLAP. 
